SUBMIT BOOK PROPOSAL
Online Store
benthambooks logo

Site Breadcrumb

Frontiers in Clinical Drug Research - Anti-Cancer Agents
View Sample

Editor: Atta-ur-Rahman

Frontiers in Clinical Drug Research - Anti-Cancer Agents

Volume 5
eBook: US $89 Special Offer (PDF + Printed Copy): US $163
Printed Copy: US $119
Library License: US $356
ISSN: 2451-8905 (Print)
ISSN: 2215-0803 (Online)
ISBN: 978-981-14-0514-3 (Print)
ISBN: 978-981-14-0515-0 (Online)
Year of Publication: 2019
DOI: 10.2174/97898114051501190501
Rate This Book

Introduction

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology researchers.

The fifth volume of the book features reviews on biochemical inhibitors (second-generation protein kinase Inhibitors, histone deacetylase inhibitors, immune checkpoint inhibitors, EGFR Tyrosine Kinase inhibitors, non-coding RNAs), apoptosis, and physical exercise therapy for cancer patients undergoing chemotherapy. The treatment strategies in this volume cover cancers such as acute myeloid leukemia, gastrointestinal cancer, breast cancer and lung cancer.


eBook: US $89 Special Offer: US $163 Printed Copy: US $119 Library License: US $356

Contributors

Editor(s):
Atta-ur-Rahman
Honorary Life Fellow
University of Cambridge
Cambridge
UK



Contributor(s):
Atsuhiro Tsubaki
Institute for Human Movement and Medical Sciences
Niigata University of Health and Welfare
Niigata
Japan


Andrew J. Sanders
Cardiff China Medical Research Collaborative, Cardiff University School of Medicine, Cardiff University, Heath Park
Cardiff
UK


Chang Gong
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetic and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital
Sun Yat-sen University
Varna
China


David Kerr
Radcliffe Department of Medicine
University of Oxford
UK


Etienne Paubelle
Hematology Department
University of Arizonaospices Civils de Lyon, Lyon-Sud Hospital
Pierre Bénite
France


Işıl Yıldırım
Beykent University, Vocational School
The University of Hong Kong
Istanbul
Turkey


Jack B. Fu
Department of Palliative, Rehabilitation Integrative Medicine
University of Texas MD Anderson Cancer Center
Houston, TX
USA


Kenneth K.W. To
School of Pharmacy, Faculty of Medicine
The Chinese University of Hong Kong
Hong Kong SAR
China


Onyinyechi Duru
Department of Oncology
Nottingham University Hospital, City Campus
Nottingham
UK


Shinichiro Morishita
Institute for Human Movement and Medical Sciences
Niigata University of Health and Welfare
Niigata
Japan


Wen G. Jiang
Cardiff China Medical Research Collaborative, Cardiff University School of Medicine, Cardiff University, Heath Park
Cardiff
UK


Wing-Sum Tong
School of Pharmacy, Faculty of Medicine
The Chinese University of Hong Kong
Hong Kong SAR
China


Xavier Thomas
Hematology Department
University of Arizonaospices Civils de Lyon, Lyon-Sud Hospital
Pierre Bénite
France


Yuequan Shi
China Medical University
Liaoning
China


Zifang Zou
China Medical University
Liaoning
China


Zihao Liu
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetic and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital
Sun Yat-sen University
Varna
China



RELATED BOOKS

..
.Alternative Remedies and Natural Products for Cancer Therapy: An Integrative Approach.
.The Management of Metastatic Triple-Negative Breast Cancer: An Integrated and Expeditionary Approach.
.Cancer Medicine in an Ayurvedic Perspective: A Critical Overview.